Back to search results

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Triple Negative Breast Cancer · Residual Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Indiana University Simon Cancer Center, Indianapolis, Indiana, United States

    Contact: Principal Investigator (Bryan Schneider, MD)

  • Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

    Contact: Study coordinator (Raven Lavoie) · Raven.M.Lavoie@hitchcock.org · (603) 653-3661
    Contact: Study coordinator (Naomi Kornhauser) · Naomi.T.Kornhauser@hitchcock.org
    Contact: Principal Investigator (Linda Vahdat, MD, MBA)

  • NYU Langone perimutter Cancer Center, New York, New York, United States

    Contact: Study coordinator (Nancy Chan, MD) · Nancy.chan29@nyulangone.org · 212-731-5349
    Contact: Principal Investigator (Nancy Chen, MD)
Study leads

  • Linda Vahdat, MD

    Principal Investigator

    Study Principal Investigator

View source on ClinicalTrials.gov(opens in a new tab)